Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus ACHROMYCIN V.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus ACHROMYCIN V.
ACHROMYCIN vs ACHROMYCIN V
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-tRNA binding to mRNA-ribosome complex.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
250-500 mg orally every 6 hours
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic